Garrett Wealth Advisory Group LLC bought a new stake in Johnson & Johnson (NYSE:JNJ) during the third quarter, HoldingsChannel.com reports. The institutional investor bought 874 shares of the company’s stock, valued at approximately $113,000.
Other large investors also recently added to or reduced their stakes in the company. WoodTrust Financial Corp grew its holdings in Johnson & Johnson by 4.2% during the third quarter. WoodTrust Financial Corp now owns 46,335 shares of the company’s stock worth $5,995,000 after acquiring an additional 1,848 shares during the period. Park Avenue Securities LLC acquired a new position in Johnson & Johnson during the third quarter worth $2,939,000. Billeaud Capital Management Inc. grew its holdings in Johnson & Johnson by 0.4% during the second quarter. Billeaud Capital Management Inc. now owns 44,014 shares of the company’s stock worth $6,130,000 after acquiring an additional 169 shares during the period. Meeder Asset Management Inc. grew its holdings in Johnson & Johnson by 11.1% during the second quarter. Meeder Asset Management Inc. now owns 109,690 shares of the company’s stock worth $15,277,000 after acquiring an additional 10,927 shares during the period. Finally, Lucia Wealth Services LLC grew its holdings in Johnson & Johnson by 2.1% during the third quarter. Lucia Wealth Services LLC now owns 131,950 shares of the company’s stock worth $17,072,000 after acquiring an additional 2,744 shares during the period. 72.03% of the stock is currently owned by institutional investors and hedge funds.
Johnson & Johnson stock opened at $128.02 on Tuesday. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.04 and a current ratio of 1.33. The firm has a market capitalization of $337.02 billion, a price-to-earnings ratio of 15.65, a price-to-earnings-growth ratio of 2.16 and a beta of 0.69. Johnson & Johnson has a fifty-two week low of $121.00 and a fifty-two week high of $148.99. The stock’s fifty day moving average is $130.44 and its two-hundred day moving average is $134.60.
The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Tuesday, November 26th will be issued a $0.95 dividend. This represents a $3.80 annualized dividend and a yield of 2.97%. The ex-dividend date is Monday, November 25th. Johnson & Johnson’s dividend payout ratio (DPR) is 46.45%.
A number of research analysts recently weighed in on the company. Goldman Sachs Group set a $169.00 price objective on Johnson & Johnson and gave the stock a “buy” rating in a report on Tuesday, August 27th. Raymond James dropped their price objective on Johnson & Johnson from $146.00 to $145.00 and set an “outperform” rating on the stock in a report on Monday, October 14th. Wells Fargo & Co dropped their price objective on Johnson & Johnson from $157.00 to $155.00 and set an “outperform” rating on the stock in a report on Wednesday, October 16th. Credit Suisse Group upped their price objective on Johnson & Johnson from $156.00 to $158.00 and gave the stock an “outperform” rating in a report on Wednesday, October 16th. Finally, Bank of America reaffirmed a “hold” rating and set a $150.00 price objective on shares of Johnson & Johnson in a report on Tuesday, July 16th. Six equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. The stock has an average rating of “Buy” and an average target price of $151.18.
Johnson & Johnson Company Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Recommended Story: Stop Order
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.